Advanced Filters
noise

Lutherville, Maryland Clinical Trials

A listing of Lutherville, Maryland clinical trials actively recruiting patient volunteers.

Found 1,029 clinical trials
E Ebony Holliday, PhD

Early Achievements - Shaping Early Language and Literacy Skills

Language skills are important for long-term reading comprehension success. Yet there are limited instructional approaches available for prekindergarten (pre-K) teachers to use in their inclusive classrooms to boost literacy-related language skills in children with and without language delays or disorders. In the first part of this study, the investigators will …

45 - 65 years of age All Phase N/A
K Katie Lowe

Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage

Very preterm infants are prone to numerous medical complications with lifelong impact. Amongst the most serious are significant intraventricular hemorrhage (sIVH) and the subsequent progression to posthemorrhagic hydrocephalus (PHH). Currently, the only treatment for PHH is surgery, most commonly with shunts that are prone to malfunction across the lifespan. Preclinical …

12 - 2 years of age All Phase 1
R Research Coordinator

APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study

This is a prospective, 2-part, multi-center, open-label, non-randomized clinical trial to assess safety and effectiveness of APrevent® VOIS Implants for the treatment of patients with Unilateral Vocal Fold Paralysis (UVFP). In total 30 evaluable patients are planned to be enrolled.

18 - 80 years of age All Phase N/A
A Annabelle Belcher, PhD

Ketamine for Opioid Use Disorder

The goal of this clinical trial is to learn if ketamine works to reduce craving for opioids in adults entering methadone treatment for opioid use disorder. The main questions it aims to answer are: Does ketamine reduce craving for opioids in patients with opioid use disorder? Does ketamine reduce symptoms …

18 - 65 years of age All Phase 2
M Martha Cavallo, ANP

Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of the potent, broadly neutralizing anti-HIV monoclonal antibodies (mAb) PGT121.414.LS alone and in combination with VRC07-523LS soon after birth in infants exposed to HIV-1.

- 72 years of age All Phase 1
M Michael Gordon

Buprenorphine for Individuals in Jail

This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail. An open-label design will randomly assign 240 adults with moderate-to-severe OUDs who are soon-to-be-released from jail to either XR-B (n=120) or SL-B (n=120) treatment in jail followed …

18 years of age All Phase 3
R Rana Harb, MS

Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction

The goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy. The main questions it aims to answer are: Is the device safe? Does the device works well? Are the participants satisfied with the …

30 - 75 years of age Male Phase N/A
C Clinical Project Manager

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

18 years of age All Phase 3
D David Wolinsky, MD

Pregnenolone as a Treatment for Cannabis Intoxication

The present study will characterize the ability of pregnenolone to reverse the acute intoxication and associated symptoms of cannabis. Healthy adults with a history of cannabis use will be recruited to participate in a placebo-controlled, within-subject crossover study at Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). By clarifying the ability …

18 - 65 years of age All Phase 2

A Study of Brenipatide in Participants With Opioid Use Disorder

The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 144 weeks, maximum …

18 - 75 years of age All Phase 2

Simplify language using AI